argenx Banner Image


  • Ticker ARGX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
argenx Logo Image
  • 501-1000 Employees
  • Based in Boston, Massachusetts
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-onlyMore approved neonatal Fc receptor (FcRn) blocker in the U.S., the EU, Japan and the UK.
4.7 / 5.0 (78)

argenx reports have an aggregate usefulness score of 4.7 based on 78 reviews.


Most Recent Responsibility Report

MOST RECENT 2022 Environmental, Social and Governance Report

argenx does not currently have any hardcopy reports on ResponsibilityReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Archived Responsibility Reports

Our service enables potential investors to review the most recent and archived argenx Sustainability Report, argenx Corporate Social Responsibility Report, argenx CSR Report, argenx Corporate Responsibility, argenx CR Report, argenx Citizenship Report, argenx ESG Report, and argenx Environmental Report online.
argenx Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!